Search

Displaying results 4271 - 4280 of 10000 in total
  1. Drug

    2,3-Dimercapto-1-propanesulfonic acid

    go.drugbank.com/drugs/DB15967
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    t-Butylhydroquinone

    go.drugbank.com/drugs/DB07726
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Ranirestat

    go.drugbank.com/drugs/DB05327
    Investigational

    It has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy. … Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels

  4. Drug

    Apolizumab

    go.drugbank.com/drugs/DB06467
    Investigational

    Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers.

  5. Drug

    Amoxapine

    go.drugbank.com/drugs/DB00543
    Approved

    The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. … In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake.

  6. Drug

    R-348

    go.drugbank.com/drugs/DB06321
    Investigational

    Synonyms: 5-Fluoro-N-(4-methyl-3-propionylaminosulfonylphenyl)-N'-(4-(prop-2-ynyloxy)phenyl)-2,4-pyrimidinediamine
  7. Drug

    MDX-1379

    go.drugbank.com/drugs/DB05329
    Investigational

    This drug is underinvestigation to treat malignant melanoma.

  8. Drug

    Bertilimumab

    go.drugbank.com/drugs/DB05429
    Investigational

    Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development. … It is developed by MedImmune for the treatment of Allergic Rhinitis.

  9. Drug

    IMC-1C11

    go.drugbank.com/drugs/DB06101
    Experimental

    IMC-1C11 is an anti-angiogenesis agent. … It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation.

  10. Drug

    Bentoquatam

    go.drugbank.com/drugs/DB00516
    Approved

    Bentoquatam is a topical medication intended to act as a shield against exposure to the irritating substance urushiol, found in plants such as poison ivy or poison oak. … Bentoquatam contains bentonite, a clay, and is only effective as long as the film is visible on the skin.